Indaptus Therapeutics Inc SEC Filings

SINO LION VENTURES Ltd has become a major shareholder of Indaptus Therapeutics, Inc. by converting preferred stock into common shares. On March 19, 2026, it agreed to acquire 259,300 shares of Series AAA Convertible Non-Redeemable Preferred Stock from David Elliot Lazar. Each preferred share is convertible into 150 shares of common stock. After the transaction closed on March 23, 2026, SINO LION VENTURES Ltd submitted a notice of conversion for all of its Series AAA Preferred Stock, resulting in the issuance of 38,895,000 shares of common stock, which it now holds directly as reported on this initial Form 3. A footnote states these securities may also be deemed beneficially owned by Chenhao Xu, who disclaims beneficial ownership except for any pecuniary interest.

Indaptus Therapeutics Chief Executive Officer Junyi Dai reported ownership of 11,250,000 shares of common stock. This position reflects the full conversion of 75,000 shares of Series AAA Convertible Non-Redeemable Preferred Stock, which were acquired under a securities purchase agreement and then immediately converted after closing.

Indaptus Therapeutics, Inc. (INDP) disclosed a new investor group led by Yun Yao acquiring and converting preferred stock into a large common equity position. The group bought Series AA and Series AAA Preferred Stock for an aggregate $11,200,000 under a Securities Purchase Agreement signed on March 19, 2026.

Following conversion on March 24, 2026, Yun Yao beneficially owns 41,991,000 common shares, or 37.8% of the class, Sino Lion Ventures Limited and its controller Chenhao Xu each report 38,895,000 shares, or 35.0% each, while Junyi Dai and Ting Yang each hold 11,250,000 shares, or 10.1%, and Lina Deng holds 5,550,000 shares, or 5.0%. All percentages are based on 111,178,324 common shares outstanding as of March 30, 2026, after giving effect to the conversion.

The filing notes the Reporting Persons may be deemed a “group” solely for purposes of the Purchase Agreement and related transactions, and they collectively may be deemed to share beneficial ownership of 108,936,000 common shares, while each disclaims beneficial ownership of others’ shares beyond their pecuniary interest. In connection with the closing on March 23, 2026, Junyi Dai was appointed Chief Executive Officer and a director, signaling an aligned management and ownership shift.

Indaptus Therapeutics reported a change in control tied to earlier issuances of Series AA and Series AAA Convertible Preferred Stock. David Lazar had purchased 300,000 Series AA and 700,000 Series AAA shares, which are convertible into a combined 111,000,000 shares of common stock. He has now sold all 700,000 Series AAA shares and rights to 196,800 Series AA shares to five Purchasers for an aggregate $11.2 million. Based on full conversion of all Preferred Stock and a total of 113,242,324 common shares outstanding on that basis, the Purchasers together would beneficially own about 96.20% of the common stock, while Lazar would hold about 1.82%. Several directors, including co-CEO Jeffrey Meckler, resigned, and Lazar stepped down as co-CEO and Chairman while remaining on the board. The board appointed Junyi Dai as Chairman effective March 18, 2026 and as Chief Executive Officer effective at closing of the March 2026 share sale.

Indaptus Therapeutics’ major shareholder David E. Lazar has sharply reduced his economic stake and stepped down as co‑Chief Executive Officer while remaining on the Board. He entered a March 2026 securities purchase agreement to sell 700,000 shares of Series AAA Preferred Stock and 196,800 shares of Series AA Preferred Stock for an aggregate $11,200,000.

These preferred shares are convertible into a total of 108,936,000 common shares. After closing on March 23, 2026, Lazar retains 103,200 Series AA Preferred shares, convertible into 2,064,000 common shares. Based on 2,242,324 common shares outstanding as of March 16, 2026 plus his remaining convertibles, the filing reports beneficial ownership of approximately 47.93%, which would drop to about 1.82% after other purchasers convert their preferred stock.

Indaptus Therapeutics director David E. Lazar sold a large block of the company’s convertible preferred stock. On March 23, 2026, he completed a Securities Purchase Agreement under which he sold all 700,000 shares of Series AAA Preferred Stock, which were convertible into 105,000,000 shares of common stock, and 196,800 shares of Series AA Preferred Stock, which were convertible into 3,936,000 shares of common stock. Following this transaction, he retained 103,200 shares of Series AA Preferred Stock, convertible into 2,064,000 shares of common stock. Both the Series AA and Series AAA Preferred Stock are perpetual and convertible at the holder’s option for no additional consideration.

Indaptus Therapeutics reports a transformative year marked by a recapitalization, governance changes and a halt to clinical development. On December 22, 2025 it sold 300,000 Series AA and 700,000 Series AAA preferred shares to David E. Lazar for $6.0 million, each share priced at $6.00. These series are convertible into a combined 111,000,000 common shares, and Mr. Lazar is now the beneficial owner of about 96.4% of the company’s common stock on an as-converted, fully diluted basis.

Stockholders approved a large increase in authorized common shares to 1,000,000,000, a reverse stock split range, and board changes that installed multiple Lazar designees. The company repriced roughly 1.68 million warrants to an exercise price of $1.75 per share and used ATM sales, a $5.7 million convertible note, equity lines and several 2024–2025 equity/warrant financings to raise cash.

Indaptus, a clinical-stage immunotherapy developer, discontinued enrollment in its Decoy20 monotherapy and combination trials and has no current plans to start new clinical studies. It discloses substantial doubt about its ability to continue as a going concern and is evaluating a strategic transaction to invest in or acquire a target company.

Indaptus Therapeutics Inc. investor David E. Lazar has disclosed effective control of the company, reporting beneficial ownership of 111,000,000 shares of common stock, or about 98% of the class, through convertible preferred stock.

Under a Securities Purchase Agreement dated December 22, 2025, Lazar agreed to buy 300,000 shares of Series AA Preferred Stock, convertible into 6 million common shares for $1.8 million, and 700,000 shares of Series AAA Preferred Stock, convertible into 105 million common shares for $4.2 million, for total consideration of $6 million. Stockholders approved the necessary share increase and conversion on February 26, 2026.

Following this deal, Lazar became Co-Chief Executive Officer and a director, and is expected to serve as Chairman of the Board. He also obtained the right to recommend up to three additional director nominees at a future stockholder meeting and has participation rights in future Indaptus financing transactions.

Jabbour Jerome D reported acquisition or exercise transactions in this Form 4 filing.

Indaptus Therapeutics director receives stock option grant. Indaptus Therapeutics, Inc. granted director Jerome D. Jabbour options to buy 25,000 shares of common stock under its non-employee director compensation program. These options vest over three years in equal quarterly installments, conditioned on his continued service on the board.